Biogen (BIIB)
NASDAQ: BIIB · Biotechnology · Cambridge, MA
Our rating: Cautious
Cautious reaffirmed at $254.46, moderate conviction, November 4, 2026.
Breaks if: The Cautious call is wrong if Biogen reports two consecutive quarters of year-on-year revenue growth at or above 7%, demonstrating that a new-product ramp is genuinely offsetting franchise erosion at scale; or if both the October and November patent invalidations are reversed on appeal and confirmed within 12 months. A sustained move above $315 without that fundamental evidence would also compel a reassessment.
Key figures
| Market value | $36.9B |
|---|---|
| Revenue, last 12 months | $10.3B |
| Net income, last 12 months | $348M |
| Free cash flow, last 12 months | $2.1B |
| Price to earnings | 106.2× |
| Free cash flow yield | 5.6% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | 1.9% |
| Beta to the S&P 500 | 0.49 |
| Volatility, annualized | 31.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $2.8B | 10.6% | $-0.14 | $600M |
| June 30, 2026 | $2.7B | 3.4% | $0.66 | $408M |
| March 31, 2026 | $2.5B | 1.9% | $2.15 | $594M |
| December 31, 2025 | $2.3B | −7.1% | $-0.35 | $468M |
| September 30, 2025 | $2.5B | 2.8% | $3.17 | $1.2B |
| June 30, 2025 | $2.6B | 7.3% | $4.33 | $134M |
| March 31, 2025 | $2.4B | 6.1% | $1.64 | $222M |
| December 31, 2024 | $2.5B | 2.9% | $1.83 | $722M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $2.33B: Claude 72%, Gemini 90%, Mistral 90%
- Diluted earnings per share are above zero: Claude 55%, Gemini 55%, Mistral 58%
- Free cash flow for the quarter is at least $0.47B: Claude 58%, Gemini 80%, Mistral 60%
18 ledger entries and 42 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.